You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical characteristics at baseline of the study participants with or without incident CV events

From: Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study

  All HIV n = 369 CV events N = 34 No CV events N = 335 Univariate p
Age, years 43.0 ± 9 53.8 ± 12 41.9 ± 8 <0.001
Male, n (%) 232 (62.9) 30 (88.2) 202 (60.3) 0.001
Follow-up, years (median) 10.0 9.8 10 ns
Body mass index, kg × m−2 24.2 ± 4 24.7 ± 5 24.1 ± 4 0.530
Italian “Progetto CUORE” risk, % 3.9 ± 7 13.0 ± 13 2.9 ± 5 <0.001
European SCORE, % 1.3 ± 2 4.2 ± 4 1.0 ± 2 <0.001
Global Framingham CVD risk, % 9.3 ± 11 23.5 ± 17 7.8 ± 10 <0.001
Cigarette smoking, n (%) 199 (53.9) 24 (70.6) 175 (52.2) 0.041
Systolic blood pressure, mm Hg 130.5 ± 17 139.7 ± 20 129.5 ± 16 0.008
Diastolic blood pressure, mm Hg 82.3 ± 10 86.5 ± 11 81.2 ± 10 0.024
Pulse pressure, mm Hg 48.2 ± 11 53.2 ± 13 47.7 ± 11 0.020
Treated hypertension, n (%) 34 (9.2) 9 (26.5) 25 (7.5) <0.002
Total cholesterol, mg/dL 180.9 ± 48 174.2 ± 47 181.5 ± 52 0.420
High-density lipoprotein cholesterol, mg/dL 54.6 ± 20 50.6 ± 19 54.9 ± 19 0.218
Statin therapy, n (%) 22 (6) 5 (14.7) 17 (5.1) 0.410
Glucose, mg/dL 89.0 ± 23 111.7 ± 46 86.7 ± 18 <0.003
Diabetes, n (%) 27 (7.3) 12 (35.3) 15 (4.5) <0.001
CDC stage C3, n (%) 105 (28.5) 14 (41.2) 91 (27.2) 0.084
Baseline CD4 lymphocyte mm3 501 ± 309 521 ± 319 500 ± 308 0.714
Baseline HIV-RNA < 50 copies/mL, n (%) 256 (69.4) 25 (73.5) 231 (69.0) 0.581
Nadir CD4 lymphocyte mm3 186 ± 162 176 ± 158 187 ± 162 0.720
Zenit HIV-RNA, copies/mL (log10) 5.0 ± 0.8 5.1 ± 0.9 5.0 ± 0.8 0.336
Hepatitis C infection, n (%) 111 (30.2) 13 (38.2) 98 (29.3) 0.282